ARS Pharmaceuticals, Inc.

SPRY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $41.3M $50.8M $71.0M $210.5M $60.1M $386.6M $10.5M
Accounts Receivable $25.3M $8.2M $0
Inventory $31.4M $10.5M $0
Total Current Assets $284.9M $334.3M $231.7M $277.7M $60.7M $390.7M
Property, Plant & Equipment $2.5M $1.1M $574.0K $329.0K $72.0K $1.6M
Goodwill
Intangible Assets (Excl. Goodwill) $14.5M $7.4M $0
Total Assets $327.7M $351.2M $233.2M $281.4M $61.4M $394.8M
Liabilities
Accounts Payable $5.7M $9.9M $759.0K $1.7M $1.8M $2.6M
Total Current Liabilities $39.1M $23.4M $2.4M $5.4M $8.2M $9.6M
Long-Term Debt $96.4M $0
Total Liabilities $213.4M $94.4M $2.4M $8.5M $16.7M $11.9M
Stockholders' Equity
Retained Earnings $-294.6M $-123.3M $-131.3M $-76.9M $-42.3M $-96.7M
Total Stockholders' Equity $114.3M $256.8M $230.8M $272.9M $-31.3M $-14.1M $-58.8M